WaveMan
WaveMan · Company
NBP · Novabridge Biosciences
> Search tickers & screens ⌘K
LIVE
← All companies

NBP NovaBridge Biosciences (NBP) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001778016
Quote by TradingView
Form 144 · 2
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
26
13F, latest reported quarter
Conversions, 180 days
9
Codes C/M, not in net · no price filed

What the filings say about NBP

Insiders, 180 days
-$154.3K net sold
3 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$85.2K
2 notices

NovaBridge Biosciences insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, NovaBridge Biosciences insiders sold a net $154.3K of stock across 8 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Foreign private issuer: most of its insiders are exempt from SEC Form 4, but some still file it; those filings are listed below, and the record may be incomplete.

Insider
Filed
Shares
Value
Since filing
Dennis Phillip Andrew
Chief Medical Officer
SELL
2026-09-21 SECtraded 2026-09-18
8,209
$5.8K
-13.8%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jun 18, 2026.
  • The trade is 4.7% of the 173,427 shares held after it.
  • 2 other insiders sold within 30 days.
  • 26 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Dennis Phillip Andrew sold about $5.8K of NBP on Sep 18, 2026; 2 other insiders sold within 30 days and 26 funds added in the latest 13F quarter.
Cao Sean Wuxiong
Chief Bus. Development Officer
SELL
2026-09-11 SECtraded 2026-09-09
107,978
$79.9K
-14.9%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on May 14, 2026.
  • The trade is 40.5% of the 266,467 shares held after it.
  • 2 other insiders sold within 30 days.
  • 26 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Bus. Development Officer Cao Sean Wuxiong sold about $79.9K of NBP on Sep 9, 2026, the largest insider sale at the company on our record; 2 other insiders sold within 30 days and 26 funds added in the latest 13F quarter.
Xu Cong Claire
EVP, Clinical Development
SELL
2026-09-01 SECtraded 2026-08-31
3,282
$2.6K
-23.5%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Jul 6, 2026.
  • The trade is 1.1% of the 304,201 shares held after it.
  • 2 other insiders sold within 30 days.
  • 26 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Clinical Development Xu Cong Claire sold about $2.6K of NBP on Aug 31, 2026; 2 other insiders sold within 30 days and 26 funds added in the latest 13F quarter.
Xu Cong Claire
SVP, Clinical Development
SELL
2026-07-07 SECtraded 2026-07-06
4,485
$4.0K
-29.0%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jun 1, 2026.
  • The trade is 1.5% of the 298,101 shares held after it.
  • 1 other insider sold within 30 days.
  • 26 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Clinical Development Xu Cong Claire sold about $4.0K of NBP on Jul 6, 2026; 1 other insider sold within 30 days and 26 funds added in the latest 13F quarter.
Dennis Phillip Andrew
Chief Medical Officer
SELL
2026-06-22 SECtraded 2026-06-18
8,494
$5.6K
-14.9%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 5.4% of the 157,941 shares held after it.
  • 1 other insider sold within 30 days.
  • 26 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Dennis Phillip Andrew sold about $5.6K of NBP on Jun 18, 2026; 1 other insider sold within 30 days and 26 funds added in the latest 13F quarter.
8 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 3 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$154.3K over 180 days
-$88.3K over 90 days
more than 53% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
26 funds bought in last quarter
below 64% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
5.1% of the float short (float per yahoo 2026-10-26) · 3.5 days to cover · settled 2026-09-30
below 71% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch NBP

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-71.6%12M
-74%-48%-23%+3%2025-102025-122026-022026-042026-062026-082026-10 2026-04-24 · Hagler Mark Arnold bought $577.3K2026-09-09 · Cao Sean Wuxiong sold $79.9K2026-05-14 · Cao Sean Wuxiong sold $42.6K2026-06-01 · Xu Cong Claire sold $13.8K2026-09-18 · Dennis Phillip Andrew sold $5.8K2026-06-18 · Dennis Phillip Andrew sold $5.6K2026-07-06 · Xu Cong Claire sold $4.0K2026-08-31 · Xu Cong Claire sold $2.6K2026-09-18 · Dennis Phillip Andrew filed to sell $5.8K2026-09-09 · Cao Sean Wuxiong filed to sell $79.4K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns NBP: institutional holders (13F)

13F holdings, latest reported quarter
HHLR ADVISORS, LTD.
5,980,568 sh
$11.7M
MORGAN STANLEY
3,653,228 sh
$7.1M
AIHC Capital Management Ltd
2,878,033 sh
$5.6M
Siren, L.L.C.
2,004,739 sh
$3.9M
MARSHALL WACE, LLP
1,231,946 sh
$2.4M

Congress trades in NBP

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

NBP planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Dennis Phillip Andrew
Filed 2026-09-18
$5.8K
Cao Sean Wuxiong
Filed 2026-09-09
$79.4K

NBP mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco NASDAQ Future Gen 200 ETF
$43.1K position · as of 2026-05-31
0.2%
Invesco Nasdaq Biotechnology ETF
$10.9K position · as of 2026-05-31
0.0%
State Street(R) SPDR(R) S&P(R) Emerging Markets Small Cap ETF
$94.2K position · as of 2026-06-30
0.0%
iShares Biotechnology ETF
$1.2M position · as of 2026-06-30
0.0%
ProShares Ultra Nasdaq Biotechnology
$7.6K position · as of 2026-05-31
0.0%
State Street(R) SPDR(R) S&P(R) China ETF
$27.7K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $154.3K sold by insiders over 180 days, 26 funds added last quarter, $85.2K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

NBP financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Debt to equity
0.13x
current debt only, 2023-12-31; equity 2025-12-31
Cash flow to debt
n/a
needs four quarters of operating cash flow
Return on equity
n/a
fewer than four consecutive quarters of net income
Return on assets
n/a
fewer than four consecutive quarters of net income
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
$182.9M
market value at close 2026-10-23 on 2025-12-31 shares, plus current debt only, 2023-12-31, minus cash 2025-12-31
FCF yield
n/a
fewer than four consecutive quarters of operating cash flow
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenuen/an/a$27.6M-$1.6M
Operating income-$94.3M-$51.4M-$72.0M-$53.1M
Net income-$46.3M-$22.2M-$207.7M-$371.1M
EPS (diluted)-0.21-0.12-1.09-1.96
Operating cash flown/an/a-$1.3B-$1.1B
Cash$210.6M$68.3M$291.5M$342.9M
SEC XBRL, fiscal years, as known on 2026-10-27

NBP Stock Sonar score 4/7 axes

Find similar shapesCompare

NBP ranks highest on risk and compliance (58th percentile) and financial health (51st), and lowest on insider conviction (25th), among Pharma & Biotech peers.

Financial health
51
Inputs
  • Debt to equity0.13x · 51 pct, sector of 352
  • Cash flow to debtneeds four quarters of operating cash flow
Insider conviction
25
Inputs
  • Net Form 4 buying (codes P and S), 180d-$154K · 51 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
36
Inputs
  • Funds adding, latest quarter26 · 36 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
58
Inputs
  • Short interest, % of float+5.1% · 58 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Profitability, Growth, US patents
  • Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

NBP filings, in plain words

Are NovaBridge Biosciences insiders buying or selling NBP?

In the 180 days to 2026-10-27, NovaBridge Biosciences insiders were net sellers, a net $154.3K across purchases and sales reported on Form 4, by 3 sellers.

Are there planned insider sales of NBP?

Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $85.2K of stock; the latest, by Dennis Phillip Andrew, was filed 2026-09-18.

Read the full summary

In the 180 days to 2026-10-27, NovaBridge Biosciences insiders were net sellers of NBP, a net $154.3K across purchases and sales reported on Form 4 by 3 sellers. None of the 7 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $85.2K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies